| Date | Title | Description | Source |
| 15.04.2024 | Publication Annual Report – Annual Shareholders' Meeting | Publication Annual Report – Annual Shareholders' Meeting
Leuven, BELGIUM – April 15, 2024 – 05:00 PM... | einpresswi... |
| 10.04.2024 | Oxurion Receives EUR 450,000 in the framework of the Atlas F... | - | globenewsw... |
| 25.03.2024 | OXURION announces its presence at the Paris SmallCap event o... | OXURION announces its presence at the Paris SmallCap
event on March 28, 2024.
Leuven, BELGIUM - Marc... | einpresswi... |
| 21.03.2024 | Information on the Total Number of Voting Rights (Denominato... | Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atl... | einpresswi... |
| 13.03.2024 | Oxurion Receives Transparency Notification from Atlas Specia... | - | globenewsw... |
| 07.03.2024 | Oxurion Receives Transparency Notification from Atlas Specia... | - | globenewsw... |
| 05.03.2024 | Oxurion Receives EUR 300,000 in the framework of the Atlas F... | - | globenewsw... |
| 04.03.2024 | Information on the Total Number of Voting Rights (Denominato... | Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atl... | einpresswi... |
| 19.01.2024 | Information on the Total Number of Voting Rights (Denominato... | Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 10 convertible bo... | einpresswi... |
| 25.10.2023 | Oxurion Receives EUR 1.5 Million under Amended Atlas Funding... | Leuven, BELGIUM, Boston, MA, US – October 25, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR)... | einpresswi... |
| 25.10.2023 | Oxurion Receives EUR 1.5 Million under Amended Atlas Funding... | - | globenewsw... |
| 07.08.2023 | Information on the Total Number of Voting Rights (Denominato... | Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 8 convertible bon... | einpresswi... |
| 04.08.2023 | Information on the Total Number of Voting Rights (Denominato... | Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 12 convertible bo... | einpresswi... |
| 25.07.2023 | Oxurion Receives Upfront Payment of $400,000 Following Oncur... | - | globenewsw... |
| 06.07.2023 | Information on the Total Number of Voting Rights (Denominato... | /EIN News/ -- Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 6 c... | einpresswi... |
| 22.06.2023 | Information on the Total Number of Voting Rights (Denominato... | /EIN News/ -- Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 6 c... | einpresswi... |
| 15.06.2023 | Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the... | /EIN News/ -- Leuven, BELGIUM, Boston, MA, US – June 15, 2023 – 7 pm CET – Oxurion NV (Euronext Brus... | einpresswi... |
| 15.06.2023 | Information on the Total Number of Voting Rights (Denominato... | /EIN News/ -- Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 6 c... | einpresswi... |
| 15.06.2023 | Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the... | - | globenewsw... |
| 31.05.2023 | Information on the Total Number of Voting Rights (Denominato... | /EIN News/ -- Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 22 ... | einpresswi... |
| 22.05.2023 | Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the... | - | globenewsw... |
| 12.05.2023 | Information on the Total Number of Voting Rights (Denominato... | /EIN News/ -- Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 12 ... | einpresswi... |
| 05.05.2023 | Information on the Total Number of Voting Rights (Denominato... | /EIN News/ -- Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 14 ... | einpresswi... |
| 27.04.2023 | Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of... | - | globenewsw... |
| 27.04.2023 | Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of... | /EIN News/ -- Leuven, BELGIUM, Boston, MA, US – April 27, 2023 – 7:00 pm CET – Oxurion NV (Euronext ... | einpresswi... |
| 07.04.2023 | Information on the Total Number of Voting Rights (Denominato... | Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 10 convertible bo... | einpresswi... |
| 20.03.2023 | Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of... | /EIN News/ -- Leuven, BELGIUM, Boston, MA, US – March 20, 2023 – 11:30 pm CET – Oxurion NV (Euronext... | einpresswi... |
| 20.03.2023 | Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of... | - | globenewsw... |
| 02.03.2023 | Oxurion Announces Subscription Agreement with Atlas Providin... | - | globenewsw... |
| 24.02.2023 | Information on the Total Number of Voting Rights (Denominato... | /EIN News/ -- Information on the Total Number of Voting Rights (Denominator) following Conversion No... | einpresswi... |
| 12.12.2022 | Informatie met betrekking tot het Totaal Aantal Stemrechten ... | /EIN News/ -- Negma Group heeft 380 converteerbare obligaties in Oxurion geconverteerd resulterende ... | einpresswi... |
| 12.12.2022 | Information on the Total Number of Voting Rights (Denominato... | /EIN News/ -- Negma Group has converted 380 convertible bonds in Oxurion resulting in a EUR 950,000 ... | einpresswi... |
| 02.12.2022 | Informatie met betrekking tot het Totaal Aantal Stemrechten ... | /EIN News/ -- Negma Group heeft 322 converteerbare obligaties in Oxurion geconverteerd resulterende ... | einpresswi... |
| 02.12.2022 | Information on the Total Number of Voting Rights (Denominato... | /EIN News/ -- Negma Group has converted 322 convertible bonds in Oxurion resulting in a EUR 805,000 ... | einpresswi... |
| 18.11.2022 | Oxurion kondigt tussentijdse analyse aan voor KALAHARI onder... | /EIN News/ -- Tussentijdse analyse voor KALAHARI onderzoek gepland tegen jaareinde 2022 met volledig... | einpresswi... |
| 18.11.2022 | Informatie met betrekking tot het Totaal Aantal Stemrechten ... | /EIN News/ -- Negma Group heeft 56 converteerbare obligaties in Oxurion geconverteerd resulterende i... | einpresswi... |
| 18.11.2022 | Information on the Total Number of Voting Rights (Denominato... | /EIN News/ -- Negma Group has converted 56 convertible bonds in Oxurion resulting in a EUR 140,000 c... | einpresswi... |
| 18.11.2022 | Oxurion Announces Interim Analysis for KALAHARI Trial | /EIN News/ -- Interim Analysis for KALAHARI trial planned by Year-End 2022 with Full Top-Line Data E... | einpresswi... |
| 11.11.2022 | Information on the Total Number of Voting Rights (Denominato... | /EIN News/ -- Negma Group has converted 130 convertible bonds in Oxurion resulting in a EUR 325,000 ... | einpresswi... |
| 11.11.2022 | Informatie met betrekking tot het Totaal Aantal Stemrechten ... | /EIN News/ -- Negma Group heeft 130 converteerbare obligaties in Oxurion geconverteerd resulterende ... | einpresswi... |
| 04.11.2022 | Information on the Total Number of Voting Rights (Denominato... | Negma Group has converted 120 convertible bonds in Oxurion resulting in a EUR 300,000 capital increa... | einpresswi... |
| 04.11.2022 | Informatie met betrekking tot het Totaal Aantal Stemrechten ... | /EIN News/ -- Negma Group heeft 120 converteerbare obligaties in Oxurion geconverteerd resulterende ... | einpresswi... |
| 28.10.2022 | Information on the Total Number of Voting Rights (Denominato... | /EIN News/ -- Negma Group has converted 580 convertible bonds in Oxurion resulting in a EUR 1,450,00... | einpresswi... |
| 28.10.2022 | Information on the Total Number of Voting Rights (Denominato... | Negma Group has converted 580 convertible bonds in Oxurion resulting in a EUR 1,450,000 capital incr... | globenewsw... |
| 28.10.2022 | Informatie met betrekking tot het Totaal Aantal Stemrechten ... | /EIN News/ -- Negma Group heeft 580 converteerbare obligaties in Oxurion geconverteerd resulterende ... | einpresswi... |
| 30.09.2022 | Information on the Total Number of Voting Rights (Denominato... | Negma Group has converted 160 convertible bonds in Oxurion resulting in a EUR 400,000 capital increa... | globenewsw... |
| 03.09.2022 | Oxurion Announces Amendment to Funding Program with Negma Gr... | Leuven, BELGIUM, Boston, MA, US – September 2, 2022 – CET 10:30PM – Oxurion NV (Euronext Brussels: O... | einpresswi... |
| 26.08.2022 | Information on the Total Number of Voting Rights (Denominato... | Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increa... | globenewsw... |
| 29.07.2022 | Information on the Total Number of Voting Rights (Denominato... | Negma Group has converted 220 convertible bonds in Oxurion resulting in a EUR 550,000 capital increa... | globenewsw... |
| 11.07.2022 | Oxurion Announces Presentations at Upcoming Scientific and I... | Leuven, BELGIUM, Boston, MA, US – July 11, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmace... | globenewsw... |
| 30.06.2022 | Information on the Total Number of Voting Rights (Denominato... | Negma Group has converted 180 convertible bonds resulting in a EUR 450,000 capital increase and Kreo... | globenewsw... |
| 01.06.2022 | Oxurion to Participate in Upcoming Investor Conferences | Leuven, BELGIUM, Boston, MA, US – June 1, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceu... | globenewsw... |
| 31.05.2022 | Information on the Total Number of Voting Rights (Denominato... | Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increa... | globenewsw... |
| 25.05.2022 | Oxurion Announces Results of the Extraordinary Shareholders’... | Leuven, Belgium, Boston, MA, US – May 25, 2022 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR)... | globenewsw... |
| 09.05.2022 | Oxurion Announces Top-Line Results from Part A of Phase 2 IN... | Trial did not demonstrate efficacy on the key clinical endpoints
Oxurion to focus on its Phase 2 dev... | globenewsw... |
| 06.05.2022 | Oxurion Announces Results of the Extraordinary and Annual Sh... | Leuven, Belgium, Boston, MA, US – May 6, 2022 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) ... | globenewsw... |
| 05.05.2022 | Oxurion to Participate in Upcoming Conferences | Leuven, BELGIUM, Boston, MA, US – MAY 5, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceut... | globenewsw... |
| 03.05.2022 | Oxurion Announces Preclinical Data on THR-687 for the Treatm... | Leuven, BELGIUM, Boston, MA, US – May 3, 2022 – 7:10 PM CET – Oxurion NV (Euronext Brussels: OXUR), ... | globenewsw... |
| 29.04.2022 | Information on the Total Number of Voting Rights (Denominato... | Negma Group has converted 230 convertible bonds in Oxurion resulting in a EUR 575,000 capital increa... | globenewsw... |
| 11.04.2022 | Oxurion Announces Upcoming Pre-Clinical Data Presentation on... | Leuven, BELGIUM, Boston, MA, US – 11 April 2022 – 7.00 AM CET – Oxurion NV (Euronext Brussels: OXUR)... | globenewsw... |
| 01.04.2022 | Oxurion Announces Extraordinary and Annual Shareholders’ Mee... | Leuven, Belgium, Boston, MA, US - April 1, 2022 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR... | globenewsw... |
| 30.03.2022 | Information on the Total Number of Voting Rights (Denominato... | Oxurion has successfully raised EUR >10 million from leading US and European healthcare investors... | globenewsw... |
| 28.03.2022 | Oxurion to Participate in Needham Virtual Healthcare Confere... | Leuven, BELGIUM, Boston, MA, US - MARCH 28, 2022 – 8.00 AM CET – Oxurion NV (Euronext Brussels: OXUR... | globenewsw... |
| 25.03.2022 | Oxurion Publishes 2021 Annual Report | Leuven, BELGIUM, Boston, MA, US - March 25, 2022 – 09.00 PM CET – Oxurion NV (Euronext Brussels: OXU... | globenewsw... |
| 17.03.2022 | Oxurion Receives Transparency Notifications from Fidelity Ma... | Leuven, Belgium, Boston, MA, US - March 17, 2022 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXU... | globenewsw... |
| 07.03.2022 | Oxurion Successfully Closes EUR >10 Million in Private Pl... | Led by new top-tier healthcare institutional investors along with participation by current major sha... | globenewsw... |
| 03.03.2022 | OXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM LEADING ... | Leuven, BELGIUM, Boston, MA, US - MARCH 3, 2022 – 08:00 AM CET – Oxurion NV (Euronext Brussels: OXUR... | globenewsw... |
| 14.02.2022 | Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial... | Post-hoc analysis reveals >9 letter gain in mean BCVA that was maintained for the remaining four ... | globenewsw... |
| 14.02.2022 | Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial... | Post-hoc analysis reveals >9 letter gain in mean BCVA that was maintained for the remaining four ... | marketscre... |
| 11.02.2022 | Oxurion Announces Upcoming Presentation on THR-149 Phase 2 C... | Leuven, BELGIUM, Boston, MA, US – 11 February 2022 – 8.00 AM CET – Oxurion NV (Euronext Brussels: OX... | globenewsw... |
| 11.02.2022 | Oxurion Announces Upcoming Presentation on THR-149 Phase 2 C... | Leuven, BELGIUM, Boston, MA, US – 11 February 2022 – 8.00 AM CET – Oxurion NV (Euronext Brussels: OX... | marketscre... |
| 08.02.2022 | Oxurion to Participate in the 2022 BIO CEO and Investor Conf... | Leuven, BELGIUM, Boston, MA, US – February 8, 2022 – 08.00 AM CET – Oxurion NV (Euronext Brussels: O... | globenewsw... |
| 18.01.2022 | OXURION to Participate in the 10th edition of Degroof Peterc... | Leuven, BELGIUM, Boston, MA, US – January 18, 2022 – 08.00 AM CET – Oxurion NV (Euronext Brussels: O... | globenewsw... |
| 07.01.2022 | Oxurion Provides Update on Clinical Pipeline Progress | Completed Patient Enrollment for Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for treatment o... | globenewsw... |
| 04.01.2022 | OXURION to Present at the H.C. Wainwright BioConnect 2022 Vi... | Leuven, BELGIUM, Boston, MA, US – January 4, 2022 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OX... | globenewsw... |
| 04.01.2022 | OXURION to Present at the H.C. Wainwright BioConnect 2022 Vi... | Leuven, BELGIUM, Boston, MA, US – January 4, 2022 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OX... | marketscre... |
| 30.11.2021 | Information on the Total Number of Voting Rights (Denominato... | Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increa... | globenewsw... |
| 24.11.2021 | OXURION to Present at the Ophthalmology Day at BTIG | Leuven, BELGIUM, Boston, MA, US - November 24, 2021 – 07.30 AM CET – Oxurion NV (Euronext Brussels: ... | globenewsw... |
| 22.11.2021 | OXURION NV Secures EUR 10 Million Convertible Bond Financing... | Provides Additional Capital to further Develop the Company’s Innovative Pipeline of Novel Clinical A... | globenewsw... |
| 22.11.2021 | OXURION NV Secures EUR 10 Million Convertible Bond Financing... | Provides Additional Capital to further Develop the Company’s Innovative Pipeline of Novel Clinical A... | marketscre... |
| 15.11.2021 | OXURION NV - First Patient Dosed in Part B of Phase 2 KALAHA... | THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly 50% of the p... | marketscre... |
| 15.11.2021 | OXURION NV - First Patient Dosed in Part B of Phase 2 KALAHA... | THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly 50% of the p... | globenewsw... |
| 04.11.2021 | Oxurion NV Announces Initiation of Equity Analyst Coverage b... | Leuven, BE, Boston, MA, US – November 4, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR),... | globenewsw... |
| 13.10.2021 | Oxurion NV Announces First Patient Dosed in its Phase 2 Stud... | THR-687 is a potent pan-RGD integrin antagonist holding potential as a next generation first line th... | globenewsw... |
| 11.10.2021 | OXURION - Positive Phase 2 Part A THR-149 data shared at the... | Patients in the highest dose group achieved an overall mean 6.1 letter improvement in Best Corrected... | globenewsw... |
| 05.10.2021 | OXURION to Present at the Lytham Partners Fall 2021 Investor... | Leuven, BELGIUM, Boston, MA, US – 5 October, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OX... | globenewsw... |
| 30.09.2021 | Oxurion : Announces Positive Results from Part A of Phase 2 ... | Decision taken to move the highest dose of THR-149 (0.13mg) into Part B of the study based on favora... | marketscre... |
| 17.08.2021 | Oxurion NV - Publication of Positive Phase 1 Clinical Data e... | THR-687 is a potent pan-RGD integrin antagonist holding potential as next generation first line ther... | marketscre... |
| 05.08.2021 | OXURION : to Participate in Upcoming Investor Meetings | Leuven, BELGIUM, Boston, MA, US - August 5th, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: O... | marketscre... |
| 10.06.2021 | OXURION Confirms Institutional Review Board Approval and Sub... | THR-687 is a potent pan-RGD integrin antagonist
holding potential as next generation first line ther... | marketscre... |
| 17.05.2021 | OXURION NV Appoints Tom Graney, CFA as Chief Executive Offic... | Patrik De Haes M.D. becomes Non-executive Chairman
Leuven, BE and Boston, MA, US – May 17, 2021 – 7:... | marketscre... |
| 13.04.2021 | OXURION NV to Present at Wet AMD and DME Drug Development Su... | Leuven, BE, Boston, MA, US – April 13th, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), ... | marketscre... |
| 07.04.2021 | Oxurion NV – Publication in Progress in Retinal Eye Research... | Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorder... | marketscre... |
| 07.04.2021 | OXURION NV
Oxurion : Publication in 'Progress in Retinal an... | Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standar... | marketscre... |
| 06.04.2021 | Oxurion NV enters into a Capital Commitment of up to 30 Mil... | Leuven, BE, Boston, MA, US – April 6, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a b... | marketscre... |
| 31.03.2021 | OXURION to Participate in Upcoming Investor Meetings | Leuven, BE, Boston, MA, US – March 31st, 2021 – 07.30 AM CET – Oxurion NV (Euronext Brussels: OXUR),... | marketscre... |
| 08.03.2021 | OXURION to Participate in Upcoming Investor Meetings | Leuven, BE, Boston, MA, US – March 8, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a ... | globenewsw... |
